ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2012 year-end and fourth quarter on Thursday, March 14, 2013 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to discuss these results.
|Conference Call and Webcast|
|Date:||Thursday, March 14, 2013|
|Time:||9:00 a.m., Eastern Time|
|Conference Call Numbers|
|Domestic (toll free):||(877) 868-1831|
About ArQuleArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline consists of ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR), ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.